FFA Sciences LLC develops molecular assays for basic research, drug discovery and clinical medicine. Our most widely used products are ADIFAB and ADIFAB2 , fluorescent probes that can be used in a broad spectrum of applications; for example, to determine lipase activity, to measure serum unbound free fatty acid levels, to determine fatty acid binding to membranes and proteins, and in drug screening. Using our proprietary technology platform, we have created an array of new molecular assays to detect levels of unbound free fatty acids and other unbound metabolites. For instance, we have developed an assay for bilirubin. We have also developed a hand-held, battery operated ratio fluorometer to enable you to quickly and inexpensively measure unbound FFA with ADIFAB or ADIFAB2. To learn more about this instrument, click on Accufluor. Elevated levels of unbound free fatty acids are associated with several disease states including ischemia, diabetes and cancer. Unbound, rather than total free fatty acid levels, provide the most sensitive indicator of the pathologic state. The new assays we are developing in our metabolomics program will provide powerful new tools for basic research and clinical medicine. Our metabolomics program is supported in part by a grant from the NIH Roadmap initiative in Metabolomics Technology Development. We also offer services to the research community. For example, we will measure unbound free fatty acids in samples sent to our laboratory. To learn more about our services, click on services .
Gryphus Diagnostics, LLC was established in 1998 in Birmingham, AL as an innovative company focusing on the development and manufacture of rapid detection systems. The first of many of these new technologies was FDA released in May of 2000, leading the way for a host of other products undergoing investigation. In early 2003, the Company was issued a U.S. patent covering its sialidase technology platform. Gryphus'products are registered and/or have regulatory approval in several countries worldwide and marketed globally to point-of-care facilities, hospitals, and clinical laboratories through a network of established distributors and licensees. Through currently available products, investigational products awaiting release, and R & D effort promising future products, Gryphus is quickly becoming a recognized name in the medical device industry. Gryphus' primary objective is, and has always been, quality. To that end, the Company is ISO 9001:2000, ISO 13485:1996, and CMDCAS registered by Underwriters Laboratories to international standards and operates under very strict guidelines set forth by the FDA. The manufacturing plant is a cGMP facility with laboratories employing state-of-the-art equipment and highly trained, skilled individuals. This combination of an ideal scientific environment with expertise in a wide variety of disciplines has resulted in a synergistic explosion of advancements. Dedicated to the development and manufacture of products for women's health.
refers to what VPI is accomplishing by bringing to market completely automated and simple to operate instruments for earlier detection and treatment of medical conditions that impair vision and cause blindness. VPI began revenue generation from product sales in October 2004 from two models of its proprietary Automated Retinal Imaging System (ARISÔ), the ArisÔ70 and the ArisÔ110. The Aris is the world's first and only fully-automated fundus camera that takes high resolution digital images of the inside-back surface of the eye (ocular fundus that includes the retina), more rapidly and with greater precision then any other fundus camera on the market. Because it requires no highly trained technician - just about anyone with only brief training can operate the ArisÔ70 and the ArisÔ110. These products are FDA 510(k) cleared, are tested and certified in conformance with the necessary U.S., Canadian and EU product safety organizations. One U.S. patent has issued and an International (PCT) patent was allowed in December 2005. Additional U.S. and international patent filings are pending. The markets for VPI's products are growing rapidly and are expected to continue growth in excess of 15% per year for the foreseeable future, both domestically and internationally. There are five fundamental reasons for this. First, over the next several years, most of the large installed base of the old film style fundus cameras will be replaced with digital systems. This represents a nearly a $1.2 billion market migration. Second, the demand for fundus cameras will increase substantially each year because of the aging of populations and the epidemic rise in diabetes worldwide. Third, the demand for higher quality healthcare that utilizes the latest in diagnostic and treatment technologies will rise. Fourth, Ophthalmologists and Optometrists will increase the use of fundus cameras because of the new capabilities and simplicity of a product such as the Aris, which in turn will allow them to increase their profitability through Medicare and insurance carrier reimbursement codes. Finally, telemedicine is rapidly emerging as a tool for bringing vision care to rural and other underserved areas, as it has in radiology and cardiology, creating new markets within the vision care industry for easy-to-use fundus cameras such as the Aris. The strategy of the Company is to continue to develop truly unique automated devices that address large existing markets and the even larger emerging markets, and that position VPI as an innovator in vision care diagnostics. VPI was founded in 1999 by a management team that is experienced in vision, healthcare and early stage growth companies. The Company manufactures its own products in Prescott, AZ where it has the facilities and capabilities to provide the necessary quality control and production levels to meet the company's objectives for the near term. It has additional products in its development pipeline that have evolved from its R&D efforts, especially in vision care. To date the Company has been capitalized by about $6.8MM from U.S. government grants and direct investment (excluding the 5 years of sweat equity management has invested). VPI is currently seeking up to $7MM in funding to meet its demand and expand its business. The uses of proceeds are described later.
Medgraph specializes in the communications of critical diagnostic information between patients and their medical caregivers, also known as telemedicine. We leverage networking and communications to enable the automation and collection of patient diagnostic data for diabetes management. This data is subsequently presented to medical professionals in a full-color graphical format, with trending and pre-set alarm limits. Later phases integrates electronic communications and patient diagnostics expanding to include doctors communicating electronically with emergency rooms. Ultimately, Medgraph envisions the technological advancement of telemedicine reaching across state, country and national boundaries to patients all over the world. Networking of critical diagnostic information will provide a huge technical improvement to the medical field. Medgraph's long term vision vision is to convert medical test results into an electronic, standardized, visual key health indicator "report card" for all individuals. This application would be used to provide medical practitioners with access to real-time medical test data in a visual, user-friendly format. It will also allow for reliable storage and retrieval of medical test data (now used once) for varied applications, mobile and remote data entry, and global transmission of medical data with accuracy, speed, and security. Medgraph is dedicated to: Providing higher-quality patient information to improve individual healthcare Providing better patient information to healthcare professionals Enabling quicker and more informed diagnostic recommendations Creating an individualized electronic "report card" of all data related to the major causes of health problems Providing our innovative blood glucose monitoring system to increase effectiveness of diabetes management Medgraph will aid the medical profession by collecting, storing, transmitting and finally converting this health data into full-color pictorial and graphical display. The collection of key medical health data through telemedicine is currently a snapshot in time instead of a long-term trend analysis. Data presented in this manner will save time, speed interpretation, eliminate repetition, and permit electronic communication. The end result will be timely information that healthcare professionals can use to provide accurate, more-effective care and medication with less cost and effort. Visual data in an easily interpretable form, including color-coding of patient information on a wide scale, is not currently available, only Medgraph has the patented telemedicine technology to implement this concept. Medgraph believes the medical profession requires the application of networking and communications technology that has already been proven in the financial world.
http://www.qualityassuredservices.com
QAS, Inc. is a direct marketing and distribution company dedicated exclusively to point-of-care/self test diagnostic markets. We distribute to consumers, professionals and home health care nursing organizations. Our products include diagnostic test kits, instruments, reagents and associated supplies.
MonoGen develops technologies and instruments to automate anatomic and molecular pathology laboratories, which largely operate manually today. Our products target broad and well-defined segments of a diagnostic testing market currently estimated by financial analysts at $3.2 billion. Forecasts predict this market will grow to $5.1 billion over the next five years as a result of significant advances in molecular diagnostic testing, particularly in proteomics and genomics testing. These new tests offer the potential for widespread screening programs of populations at risk for cancers and infectious diseases modeled on the screening done today for cervical cancer in women.
Instant Technologies, Inc., headquartered in Norfolk, Virginia, is a leading developer and distributor of rapid test devices that include drug and alcohol testing, women's health and clinical diagnostics. Our devices are easy to operate, convenient to store and deliver results in minutes. Since 1997, we have been serving our clients with the highest quality products at competitive prices while offering superior product training and customer care as well. We welcome the opportunity to work with you. Our product lines are engineered to combine ease of use with accuracy and rapid initial results. We provide a wide variety of screening devices that are easily administered at your workplace, clinic or other location. In addition to saliva and urine drug tests we provide tests for pregnancy/ovulation, Strep A, Mono and other point of care diagnostics. Our products are designed for use in all types of industries to include Fortune 500 companies, staffing agencies, construction, transportation, hospitals and laboratories, correctional institutions, counseling services, law enforcement, schools and many others. Contact us for a full consultation and feel free to browse through our website for more product information. We look forward to serving you.
We are committed to providing the highest quality products and services for our customers and partners at fair prices. We are committed to and are passionate about developing sensing technologies that are accessible and beneficial to all mankind. We are strongly committed to being the innovation leader in miniaturized biochip sensor systems. We are committed to building value for our stakeholders. We are committed to building trust in all relationships. We value personal dignity and respect of the individual and a culture of inclusiveness, tolerance and integrity. We value open and honest communication. We respect work/life balance. We support a dynamic, risk taking, and entrepreneurial work environment.
PDSHeart is a leading Telephonic Monitoring company, constantly striving to bring the best of technology and service to the Telephonic Monitoring market. We currently operate in all 50 states throughout the United States. What does PDSHeart offer? The first fully accredited JCAHO provider of event, holter and pacer services in the nation! A contracted service available with no charge to the practice Personnel, equipment and expertise to perform the procedure All results belong to the physician Allows the physician to offer more services without spending money to add them to the practice offering 24-hour monitoring center with three locations to guarantee availability of staff and data Our Cardiac Technicians are ACLS certified; many hold CCT credentials as well Sales reps have undergone training at the Arrhythmia Technologies Institute PDSHeart is the first ...
MEDTOX Scientific, Inc. (MEDTOX) provides forensic and clinical laboratory services through its wholly owned subsidiary MEDTOX Laboratories, Inc., and manufactures and distributes diagnostic devices and other similar products through its wholly owned subsidiary MEDTOX Diagnostics, Inc. The Company has two reportable segments: Laboratory Services, which consists of the activities conducted by MEDTOX Laboratories and New Brighton Business Center LLC (NBBC); and Product Sales, conducted by MEDTOX Diagnostic. Laboratory Services include: forensic toxicology, clinical toxicology, clinical testing for the pharmaceutical industry (central laboratory services, bioanalytical and pharmacokinetic testing), clinical testing for occupational health clinics and analysis of heavy and trace metals. The Product Sales segment includes sales of a variety of on-site drug screening products and contract manufacturing. (Source: 10-K)
Zonda Incorporated is a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets. Zonda's tests utilize patented and proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets. Zonda's strong intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. Our first medical test for Chlamydia is expected to launch in the US at the end of the first quarter 2008. We believe it will compete successfully with all current technologies, including the 'gold-standard' nucleic acid amplification testing (NAAT) technology while offering several enhanced features.
PreMD Inc. (PreMD) is a predictive medicine company focused on improving health outcomes with non- or minimally invasive tools for the early detection of life-threatening diseases, particularly cardiovascular disease and cancer. The Company’s products are designed to identify those patients at risk for disease. PreMD is developing tests designed for use right at the point of care, in the doctor’s office, at the pharmacy, and eventually, in some cases, right at home. Its pipeline of products includes Coronary Artery Disease Risk Assessment Technology and Cancer Screening Tests (in clinical studies). On July 13, 2007, PreMD signed a license agreement with AstraZeneca Pharmaceuticals LP (AstraZeneca) to market and distribute its skin cholesterol test in the United States. On May 25, 2007, the Company entered into an agreement with Thermo Fisher Scientific Inc. (Thermo Fisher) to manufacture and supply PreMD with PREVU POC test kits. (Source: 20-F)
Neuro Kinetics, Inc. (NKI) is a global leader in eye tracking and neuro-otologic diagnostic systems; the company works with prominent researchers and clinicians to study and test the human neurologic, otologic and ophthalmologic systems. Incorporated in 1984, Neuro Kinetics has been the equipment and software supplier to researchers studying the brain's balance function and clinicians who diagnose and treat balance disorders. Neuro Kinetics' customers include Johns Hopkins University, Massachusetts Eye and Ear Infirmary, the Mayo Clinic, and NASA. NKI works closely with top researchers and thought leaders to engineer unique, state-of-the-art systems with digital technology, to complete various new tests. Through this close working relationship with the world's top researchers, NKI pioneers new leading-edge equipment and protocols for the clinical environment, constantly updating its technology to help the clinician more effectively diagnose and treat vestibular and neuro-otologic disorders. NKI's new patented rotational servo motor sets, the cornerstone piece of both its clinical and research systems, are precise, digital systems designed to provide high torque and high angular acceleration, and have the lowest torque ripple on the market (.1%). This unmatched motion control features precise movement with no inertial artifacts, providing for better testing data and a more accurate diagnosis. An integrated low noise mechanical bearing system provides smooth, quiet operation with high loads, allowing for the testing of patients up to 400 lbs. NKI proprietary software VESTÔ 6.0 (included with the clinical Barany Chair System) incorporates a complete battery of vestibular tests and provides an analysis of the resulting data for fast and accurate diagnosis. It provides seamless control of all testing hardware including peripherals, through simple interface screens. A large database of clinical testing results provides normative data for testing comparisons. The Barany Chair rotates using different sinusoidal and trapezoidal patterns, where the patient's vestibulo-ocular reflex is measured; the involuntary movement of the eyes during motion. Traditionally, most vestibular/neuro-otologic testing focused on the horizontal semi-circular canals. NKI multi-axis motion systems allow for expanded testing of the semi-circular canals, as well as the otolith organs, allowing for a more complete analysis of the vestibular system and a more thorough diagnosis. Eye movements can be tracked and analyzed using NKI's new patent pending I-Portal® 4D video-ocolography (VOG) system. The system is completely portable and can be used with the Barany Chair or as a stand-alone device used with other testing peripherals. NKI offers a complete line of products for neuro-otologic and balance testing, and products to support therapy for the prevention of falls.
Osmetech plc is an AIM-listed public company on the London Stock Exchange under ticker symbol OMH. Osmetech plc is incorporated in England and Wales and its main country of operations is the US. Osmetech plc was founded in 1993, developing electronic odour sensor ("e-nose") technology. IPO followed in 1994 and in 1999, the Company changed its name from Aromascan to Osmetech refocusing the business on the opportunities within the global healthcare market. With the acquisition of the OPTI (blood gas) product line from Roche Diagnostics in 2003, the Critical Care Diagnostic Division was formed, which more than doubled its level of sales revenues in 3 years through a strong network of international distributors. The Osmetech Molecular Diagnostics division was created from acquisitions of Molecular Sensing plc in October 2004 and Clinical Micro Sensors, Inc. from Motorola in July 2005. Recently, Osmetech divested its Critical Care Diagnostic Division and is now focused on accelerating the expansion and development of the Molecular Diagnostic Division.
MedMira Inc. (MedMira) is a Canadian medical biotechnology company engaged in the development, manufacturing and marketing of immunoassay-based, in-vitro diagnostic tests. MedMira specializes in developing and manufacturing diagnostic immunoassays for the detection of antigens and antibodies associated with a variety of human diseases. The Company’s products are based on its own flow-through membrane technology, which relies on specific antigen-antibody reactions allowing for the detection of disease-specific markers in clinical specimens. MedMira’s commercialized products for human immunodeficiency virus (HIV) testing include Reveal G3 Rapid HIV-1 Antibody Test, MedMira Rapid HIV Test and MiraWell Rapid HIV Test. Its hepatitis testing products include MiraWell Rapid HBV Test, MiraWell Rapid HCV Test and Multiplo Rapid HIV/HCV Antibody Test. Its other product lines include MedMira Rapid H. pylori Antibody Test, MiraWell Rapid H. pylori Test and MiraWell HIV Prevention Program. (Source: ARS)
Diagnostic Products Corporation, founded in 1971, is the global leader dedicated exclusively to immunodiagnostics. DPC's product menu includes over 75 immunoassays and more than 360 specific allergens and allergy panels. In addition, DPC addresses the chemistry and laboratory automation testing needs of its customers through partnerships with manufacturers of chemistry systems and reagents. The combined chemistry and immunoassay menu is one of the largest and most diversified available, covering most laboratory tests requested. DPC also designs and manufactures automated laboratory instrumentation, which provides fast, accurate results while reducing labor and reagent costs. DPC sells its products to hospitals, clinics and laboratories in more than 100 countries.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory